NEW YORK (AdAge.com) -- Novartis has shifted its estimated $25 million-plus Lamisil account to Deutsch, New York, from Lowe offshoot Alchemy without a review, according to executives familiar with the matter. Lamisil is an drug for toenail fungus.

Novartis, which is headquartered in East Hanover, N.J., has launched a separate review for an agency to handle direct-to-consumer work for Diovan, a drug for hypertension, executives close to the situation said.

The pitch is also believed to include a search for an agency to handle marketing to health-care professionals. Contenders could not be confirmed. Billings were uncertain.

A call to a Novartis representative was not immediately returned.